Oral administration of aureomycin is currently the method of choice. The intravenous route is occasionally used when oral administration becomes difficult by reason of excessive nausea, vomiting, or diarrhea. The intramuscular injection of aureomycin is now but little used since early reports by some workers indicated that blood levels obtained by this route were relatively low, and, more important, considerable pain was observed following intramuscular administration (Brainerd et al., 1949; Bryer et al., 1949) .
Oral administration of aureomycin is currently the method of choice. The intravenous route is occasionally used when oral administration becomes difficult by reason of excessive nausea, vomiting, or diarrhea. The intramuscular injection of aureomycin is now but little used since early reports by some workers indicated that blood levels obtained by this route were relatively low, and, more important, considerable pain was observed following intramuscular administration (Brainerd et al., 1949; Bryer et al., 1949) .
In our preliminary experimental studies the intramuscular administration of aureomycin appeared to be unusually effective, and in the present work we will report on (1) the relative effectiveness of aureomycin in experimental pneumococcus infections in mice when given orally, intravenously, and intramuscularly, and (2) the correlation between the concentration of aureomycin inhibiting the pneumococcus in vitro and in vivo.
MATERIALS AND METHODS
Type 1 pneumococcus was used throughout the work. Growth of 0.1 ml of a 1 :100 dilution of an 18-hour broth culture of this strain was inhibited by 0.04 units of penicillin and 0.12 ug of aureomycin after 18 hours' incubation at 37 C in beef heart infusion broth containing 2 per cent horse serum, pH 7.1.
Evaluation of drug effect. Drug action was determined in experimental infections of white mice (approximately 20 grams) injected intraperitoneally with 0.1 ml of a 1:100 dilution of a 16-hour culture (approximately 10,000 MLD). The relative effectiveness of the drugs and routes of administration were determined by (1) the survival rate of mice following therapy, (2) the rate of destruction of bacteria in the blood stream, and (3) the serum levels of aureomycin.
The quantitative evaluation of the rate at which the drug inhibited multiplication of the bacteria in the blood stream was determined by obtaining a drop (approximately 0.03 ml) of tail blood at regular intervals and placing the drop obtained in a petri dish containing 2 ml of broth; 1 ml was then removed and 10-fold dilutions were made. Plate counts were obtained by adding, to 1 ml of each dilution, melted Difco blood agar base containing 0.5 per cent glucose and 2 per cent horse serum. Plates were read after 24 hours. Aureomycin serum levels were determined by the method of Dornbush and Pelcak (1948) Relative activity of penicillin and aureomycin following intramu-scular injection. Groups of 10 mice were inoculated intraperitoneally with pneumococci and immediately treated with 1,650 units (1 mg) of penicillin or 1 mg of aureomycin intramuscularly. All of the 10 mice given the penicillin died in 48 to 72 hours, but the mice treated with the aureomycin survived the 12-day observation period. These results were unexpected, since equal weights of the two drugs were used and the pneumococcus was more sensitive to penicillin than to aureomycin. This marked difference in the action of penicillin and aureomycin was studied further by determination of the rate at which the drugs inhibited the multiplication of the bacteria in the mice. This was done by means of bacterial counts of tail blood obtained at various intervals of time after treatment. The results are shown in figure 1. The counts are the averages obtained from five separate assays. It can be seen that although penicillin effected a prompt reduction in the count, which was sustained for 10 hours, this was followed by a sharp rise at 24 hours and the mice all died in 48 to 72 hours. One mg of aureomycin effected a slower reduction in the bacterial count, but the effect was sustained and at 24 hours few or no bacteria were found in the blood and all the mice survived the 12-day observation period.
The most reasonable interpretation of the data was that aureomycin, though it inhibited the multiplication of the bacteria at a considerably slower rate than did the penicillin, was adsorbed from the site of injection or excreted from the blood stream (or both) at a far slower rate than penicillin, and, by reason of this slow adsorption or excretion, maintained a prolonged therapeutic effect.
Duration of drug action following intramuscular injection. The duration of the bacteriostatic action of penicillin was first determined by injecting 3 groups of 5 mice each with 1 mg of penicillin intramuscularly and then, after 3, 5, and 7 hours, inoculating pneumococci intraperitoneally. Any residual bacteriostatic action of penicillin could then be detected by the slower rate of multiplication of the pneumococci when compared with the untreated controls. As will be indicated later, this challenge technique is a more sensitive method for the determination of. the prolonged action of the drug than the determination of serum levels. Counts taken 1, 5, and 7 hours after the pneumococcus challenge showed that there was some residual penicillin after 3 hours, as indicated by the slower rate of multiplication in the treated mice than in the controls. However, in mice challenged 5 hours after the initial injection of penicillin, the Mice were injected intraperitoneally with 0.1 ml of a 1:10 dilution of pneumococci and treated immediately with aureomycin and penicillin.
rate of multiplication was precisely the same as in the controls. It was therefore concluded that there was no residual bacteriostatic action of penicillin 5 hours after 1 mg of the drug was injected intramuscularly. It is of interest to note that, although all the penicillin was excreted in 5 hours, the bacterial count in the blood did not increase significantly for 10 hours (figure 1). These results indicate that for 5 hours after the elimination of the penicillin the bacteria were not capable of rapid multiplication in the blood stream. This is further evidence that the maintenance of a constant blood level is not so critical a factor as was once assumed.
Since preliminary results had indicated that the action of intramuscular aureomycin was considerably more prolonged than that of penicillin, the following M. LEIN experiments were conducted to determine the extent of this effect with aureomycin. Groups of 10 mice were injected intramuscularly with varying concetrations of aureomycin. The mice were then challenged with type 1 pneumococci after 1, 2, 3, 4, 5, 6, or 7 days. They were observed for 12 days, and the survival rate was determined as follows: Since all control mice died within 48 hours, treated mice surviving 3 days were given a score of 1; mice surviving 4 days were given a score of 2, etc. Mice were observed for 12 days and those surviving the Twenty mice given 10,000 MLD of type I pneumococcus I.P.-all dead in 2 days * A score of 0 days indicates that the average survival time of 10 treated mice was no greater than the untreated controls (2 days). A score of 10 days indicates that all of the mice survived the 12-day observation period. observation period were given a score of 10. This prolonged observation period was used since mice regularly showed a delayed time of death when challenged after intramuscular aureomycin. The results as recorded in table 1 (A) represent the average survival time in days for each of the 10 mice in a group. It can be seen that mice given 0.1 mg of aureomycin intramuscularly and challenged after 24 hours did not show a survival rate greater than that of the untreated controls, though counts of mouse blood at 1, 5, and 7 hours indicated that there was an initial inhibitory action. With increase in dosage there was a marked increase in survival rate. One mg of aureomycin, which had protected all mice when chal-lenged immediately, still protected mice 'to a marked degree when they were challenged after 24 hours. A single injection of 4 mg of aureomycin, the highest concentration tested, protected mice to a significant degree when challenged after 6 days. All intramuscular injections were obviously painful to the mice, though no residual tissue damage was observed at the site of injection until the 4 mg dose was reached, when definite necrosis was observed.
As was indicated above, the prolonged action of intramuscular aureomycin could be due either to a slow adsorption from the site of inoculation or a slow rate of excretion from the blood stream. That the prolonged effect was not primarily due to a slow rate of excretion from the blood is shown by the results given in table 1 (B). When 2 mg of aureomycin were injected intravenously, all of the drug was excreted in 24 hours, as determined by the absence of both a significant protective action and a detectable serum level (table 2) . On the other hand, mice given 2 mg of aureomycin intramuscularly still possessed some residual aureomycin when challenged after 4 days. Our results therefore indicate that, following intramuscular injection, aureomycin remains at the site of injection, probably by reason of its relative insolubility at the pH of the tissues, and is slowly released from the site with the maintenance of a relatively sustained protective blood level. It should be noted that, though aureomycin was found very labile in solution at 37 C with 50 to 96 per cent of its activity lost after 24 hours (Price, Randall, and Welch, 1948) , it is not particularly labile in the mouse following intramuscular injection, since active aureomycin can be demonstrated 6 days after a single large injection.
If one compares the survival of mice given 5 mg of aureomycin by gavage and 0.5 mg intramuscularly and challenged after 24 hours (table 1), it is clear that one must give orally 10 times the intramuscular dose to achieve a comparable therapeutic effect. The same relative degree of protection was observed when mice were challenged immediately. This oral versus intramuscular ratio is of the same order as that obtained with penicillin and indicates that the oral route, though certainly effective in adequate dosage, is not, on a weight basis, an efficient route of administration.
Serum levels of aureomycin following intramuscular, oral, and intravenous administration. Mice were given aureomycin orally, intramuscularly, d intravenously and bled at various intervals of time; the serum levels were determined as described under "Materials and Methods." The sera from 3 mice were pooled for each assay. The results are shown in [VOL. 60 levels that were detectable at 1 and 4 days, respectively. There is here also a significant discrepancy between the in vitro sensitivity of the pneumococcus and serum. Each reading based on sera from the protective action of the 4-day blood levels, which will be considered below.
Relationship between blood levels and rate of destruction of pneumococci. Fol-lowing the administration of 2 mg of aureomycin intravenously, the blood level after 10 minutes was over 60 times greater than that obtained when 0.5 mg of aureomycin was given intramuscularly. After 1 hour this serum level was still more than 10 times as high as that obtained after intramuscular administration of 0.5 mg. At 4 hours the blood levels were essentially similar. Though the 2 mg of aureomycin intravenously did not protect mice to a greater degree than did the 0.5 mg given intramuscularly, it was of interest to determine whether the rate of killing of the pneumococci was greater during the initial period of the high blood level obtained following the intravenous injection of aureomycin. Mice were therefore given 2 mg of aureomycin intravenously and 0.5 mg intramuscularly and challenged ediately with 0.5 ml of a 1:10 dilution of a 16-hour culture of pneumococci. Counts were obtained at 1 and 4 hours. The results are shown in figure 3 , which are the average results of five separate assays. As can be seen, the high blood level of aureomycin obtained after intravenous administration did not increase the rate of killing above that obtained with the 0.5 mg of intramuscular aureomycin. The observed difference is wvithin the experimental error of the technique used. It is clear, therefore, that in the case of pneumococcal infection in mice the very high aureomycin serum levels obtained after intravenous inoculation are rapidly excreted without being efficiently utilized, since they neither increase the rate nor the total number of pneumococci killed. [VOL. 60
Relationship between serum level, protective action, and sensitivity of pneumococcus to aureomycin. As shown in table 2 and figure 2, the serum levels of aureomycin 4 days after a single intramuscular injection of 3 mg were never higher than 0.06 ug per ml and more frequently were considerably below this figure.
At 5 days the serum levels were regularly below 0.03 ,ug per ml. The pneumococcue used in our tests required 0.12 pg of aureomycin for in vitro inhibition, yet mice challenged after 4 days showed a significant degree of protection against this pneumococcus, and even after 5 days some protection was observed. These results show that there was not a precise correlation between serum levels and in vitro sensitivity, and the recorded blood levels were either too low or the pneumococcus was considerably more sensitive than the in vitro assay indicated. In the determination of the serum levels of aureomycin the serum was promptly separated from the clotted blood and assayed either immediately or placed in the deep freeze for not more than 3 days, a delay that we found did not reduce the level of aureomycin. Once this precaution was observed there did not appear to be any way of determining whether any loss occurred in the activity of aureomycin from the time of its removal from the mouse to the time of assay. However, we did find that the in vitro sensitivity of the pneumococcus varied with the time of reading the assay and the size of the inoculum. In time of reading. The 9-hour readings were considerably lower than the 18-hour readings, which were very similar in all assays, requiring either 0.12 or 0.25 units of aureomycin for complete inhibition of growth. This sensitivity of the pneumococcus to aureomycin is of the same order as that reported by Gocke, Collins, and Finland (1949) . In view of the well-known lability of aureomycin in broth at 37 C (Price, Randall, and Welch, 1948) , the observation that 18-hour readings are relatively inaccurate is not surprising. It is not possible to say which of the sensitivity readings indicated in table 3 is precisely related to the blood level and protective action of aureomycin in the mouse. The 9-hour readings of 0.007 to 0.015 obtained withtryptose phosphate broth, yeast extract, and serum inoculated with 0.1 ml of a 1:10,000 dilution of pneumococci offer the most reasonable cor- aureomycin. Where the limiting factor of pain is not decisive, large single dos could be used to obtain a prolonged effect. There is the additional complicating factor of necrosis obtained at the extremely large dose level of 4 mg of aureomycin, but it was possible to give four 1-mg intramuscular injections at different sites simultaneously and almost equal the prolonged effect of the single 4-mg dose.
The rate of excretion of aureomycin and penicillin is considerably more rapid in the mouse than in man (Sanders et al., 1949) ; hence the absolute time intervals for excretion of the drugs are not directly related to those observed in man. However, the relative activity of the drug when given by the oral, intravenous, and intramuscular routes may be considered as suggesting the human pattern.
In all studies of blood levels of aureomycin and in vitro sensitivity to the drug it has been generally assumed that, given a reasonably sensitive technique, the concentration inhibiting growth in vitro is a measure of the concentration needed to inhibit growth in vivo. The precise correlation between the concentration of the drug inhibiting growth in vitro and the concentration inhibiting growth in vivo has not been determined and would be difficult with the fluctuating blood levels one obtains following oral or intravenous administration. The relatively constant blood levels we obtained follo'wing intramuscular administration permitted the study of such correlation. Our results indicate that the present concept of a minimal therapeutic blood level is too high. A level as high as 2 ,g per ml of serum has been suggested (Randall, Taylor, and Wellman, 1949) The very high initial blood levels obtained after intravenous injection of aureomycin did not increase the rate of destruction of the pneumococti over that obtained with lower blood levels.
The concentration of aureomycin required to inhibit growth in vitro of a type 1 pneumococcus after 18 hours' incubation at 37 C is 5 to 10 times greater than the concentration required to inhibit growth in vivo.
